Rxcurve
Medicare Part B payment limits Effective October 1 – December 31, 2026 Posted by CMS September 17, 2026

AfliberceptBevacizumabDenosumabEculizumabEpoetin alfaFilgrastimInfliximabNatalizumabPegfilgrastimRanibizumabRituximabTocilizumabTrastuzumabUstekinumab

Biosimilars · Tocilizumab

Avtozma is paid 41.8% below Actemra

3 biosimilars bill against Actemra (J3262). On average they are paid ↓ 23.8% relative to the reference product per 1 MG in 4Q26.

  • Actemra (reference)
  • Avtozma
  • Tyenne
  • Tofidence
Payment limit per 1 MG, last 8 quarters. Reference product as the thick navy line, biosimilars in teal and other colors.

All products

ProductCodeCMS descriptionPer 1 MGvs. referenceCMS 8% add-on note8 quarters
Actemra J3262 Tocilizumab injection $5.325 Reference –
Avtozma Q5156 Inj, tocilizumab-anoh, 1 mg $3.098 ↓ 41.8% Yes
Tyenne Q5135 Inj, tyenne, 1 mg $4.37 ↓ 17.9% Yes
Tofidence Q5133 Inj, tofidence, 1 mg $4.706 ↓ 11.6% Yes

Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.